BiotechTube
Home/EmeraMed/Boyd Haley, PhD
BH

Boyd Haley, PhD

Chief Scientist & CEO

EmeraMed

Therapeutic Areas

Heavy Metal ToxicityCOPDInfectious Disease

EmeraMed Pipeline

DrugIndicationPhase
Emeramide for Mercury ToxicityMercury PoisoningPhase 2
Emeramide for COPDChronic Obstructive Pulmonary DiseasePhase 2
Emeramide for COVID-19COVID-19Preclinical

Leadership Team at EmeraMed

RK
Ragnar Klingberg
Board Member
KW
Kathryn Wachsman
Board Secretary
PR
Paul Reicherter, MD
Board Member
View full EmeraMed profile